Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best cheap stocks that will skyrocket. On January 13, analysts at Cantor Fitzgerald reiterated an Overweight rating on the stock and set a $123 price target. The positive stance is in response to the company reaching 12.5% market share in its Prader-Willi Syndrome (PWS) treatment, Vykat.

Consequently, the company is expected to generate $98.67 million in revenue even as the discontinuation rate on the flagship drug remains at 15%. Cantor Fitzgerald expects Soleno to add 1,000 patients every 9 to 12 months, representing 10% of the total addressable market. While the company has enjoyed strong adoption among younger patients, there is a significant shift toward older patients, including those aged 27-42 and 43-65.

Meanwhile, Baird lowered its price target on the stock to $107 from $121 while reiterating an Outperform rating. The new price target represents significant upside potential given that the stock trades at about $41 a share. The research firm remains bullish on the company’s stock, projecting sales of $90 to $92 million for its Vykat drug, exceeding its $82 million estimate.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a biopharmaceutical company focused on developing treatments for rare diseases, most notably Prader-Willi syndrome (PWS), a complex genetic disorder. Its lead product, VYKAT XR is the first FDA-approved therapy for hyperphagia (excessive hunger) in PWS patients aged 4 and older, a major symptom of the condition.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.